



Embla Medical hf: Embla Medical completes share issue following closing of majority share investment in Streifeneder ortho.production GmbH

Announcement no. 41/2025

3 September 2025

Reference is made to announcement no. 39/2025 published on 29 August 2025 (Embla Medical closes the majority share investment in Streifeneder ortho.production GmbH).

Reykjavik, Iceland/Copenhagen, Denmark, 3 September 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced that in connection with the majority investment in Streifeneder ortho.production, the Board of Directors of Embla Medical resolved to utilize the authorization in Article 5, paragraph 1, of the Articles of Association to issue 2,805,135 new shares in Embla Medical. The price of each new share was DKK 33.26, and the total value of the share capital increase was thus DKK 93 million (EUR 12.5 million).

The sellers of Streifeneder ortho.production will subscribe for all the new shares. The sellers have also agreed to a two-year lock-up period from closing for all the new shares.

Registration of capital increase completed

The capital increase of ISK 2,805,135 nominal value was registered with the Icelandic Register of Enterprises today.

The new shares are expected to be admitted to trading on Nasdaq Copenhagen with effect from 5 September 2025.

Embla Medical's total share capital

According to Article 19 of the Icelandic Act on Issuers' Disclosure Requirements and Flagging Obligations no. 20/2021, an issuer shall make public, as soon as possible, the total number of shares and voting rights following an increase in share capital.

Embla Medical's total share capital is now ISK 430,441,257 nominal value divided into the same number of shares with a nominal value of ISK 1 each following the share capital increase referred to above. Each share carries one vote and hence the total number of voting rights is 430,441,257.

Enclosed are Embla Medical's updated Articles of Association, dated 29 August 2025.

Further information Embla Medical

Klaus Sindahl

Head of Investor Relations

M: +45 5363 0134

E: ksindahl@emblamedical.com

Embla Medical press releases by e-mail

If you wish to receive Embla Medical press releases by e-mail, please register at <http://www.emblamedical.com/investors>

About Embla Medical

Embla Medical (Nasdaq Copenhagen: EMBLA) was founded in Reykjavik in 1971 with the mission to improve people's mobility. Embla Medical is home to several brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing and supports solutions; FIOR & GENTZ, an innovative developer of neuro orthotics; and College Park Industries, creators of custom-built prosthetic solutions. Embla Medical also provides patients with world-class care through a global network of Orthotic and Prosthetic (O&P) facilities. Embla Medical is committed to sustainable business practices and is signatory to the UN Global Compact, UN Women's Empowerment Principles, and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has more than 4,000 employees. www.emblamedical.com

Embla Medical was formerly listed as Össur (OSSR) on Nasdaq Copenhagen until 8 April 2024.